Browse studies, page 1075
Page 1075 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Innovative insights into the effects of a high‐sucrose diet on pancreatic health and the therapeutic role of empagliflozin in type 2 diabetes: An experimental study Animal Models and Experimental Medicine, 2025
- The potential neuroprotective effect of empagliflozin against depressive-like behavior induced by chronic unpredictable mild stress in rats: Involvement of NLRP3 inflammasome European Journal of Pharmacology, 2025
- The Effects of Low-dose Empagliflozin on Cardiac Function in a Rat Model of Streptozotocin-induced Diabetes Research Square, 2021
- The Molecular Effect of Empagliflozin (SGLT2i) on the Autophagy Pathway in Type 2 Diabetic Mice Model With Diabetic Nephropathy Journal of the American Society of Nephrology, 2022
- Elucidation of Glomerular Hemodynamic Changes by SGLT-2 Inhibitors and ARBs in a Type 2 Diabetic Animal Model Using In Vivo Imaging Journal of the American Society of Nephrology, 2021
- Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease AJP - Renal Physiology, 2021
- Lack of evidence for improved β-adrenoceptor-mediated papillary muscle contraction by low-dose empagliflozin treatment in a rat model of streptozotocin-induced diabetes Journal of Research in Pharmacy, 2026
- #993 The molecular effects of SGLT2i (Empagliflozin) on α-Klotho and Nephrin/Podocin proteins in type II diabetic mice model Nephrology, Dialysis and Transplantation, 2024
- P0101INHIBITION of tumor necrosis factor alpha enhanced antifibrotic effect of empagliflozin in an animal model with renal insulin resistance 2020
- The Influence of Empagliflozin on the Expression of Mitochondrial Regulatory Proteins in Human Myocardium in an Ex Vivo Model of Short-Term Atrial Tachypacing International Journal of Molecular Sciences, 2025
- Effect of sodium‐glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes Journal of Cellular Biochemistry, 2018
- SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics JACC CardioOncology, 2025
- SGLT2 inhibitor empagliflozin prevents anthracycline-induced cardiotoxicity in a large-animal model European Heart Journal, 2024
- The Impact of Aircraft Noise Exposure on the Efficacy of Empagliflozin Therapy in an Animal Model of Obesity Diabetes & Obesity International Journal, 2025
- Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation Cardiovascular research, 2024
- Empagliflozin Inhibits Cadmium-Induced Hepatic Cell Apoptosis Through Endoplasmic Reticulum Stress and Autophagy Pathways Biological trace element research, 2025
- Combining sodium-glucose co-transporter-2 inhibitor with mesenchymal stem cells and brown adipose tissue (BAT) and white adipose tissue (WAT) transplantation to mitigate the progression of diabetic kidney disease: a pre-clinical approach Stem cell research & therapy, 2025
- Mechanism of Jiming Powder in ameliorating heart failure with preserved ejection fraction based on metabolomics Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2023
- Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion Basic research in cardiology, 2026
- Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024
- Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression International journal of molecular sciences, 2023
- Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways Cardiovascular toxicology, 2021
- Empagliflozin Inhibits Neuronal Ferroptosis Induced by Oxygen-Glucose Deprivation/Reoxygenation by Activating the Nrf2/HO-1 Pathway Molecular neurobiology, 2025
- Empagliflozin-Pretreated Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Attenuated Heart Injury Oxidative medicine and cellular longevity, 2023
- Empagliflozin beyond antidiabetic effect: Amelioration of cyclophosphamide-induced testicular toxicity in rats: Orchestrating klotho/Nrf-2/PPAR-γ/NF-κB/ Bax/Bcl-2 cues Biochemical pharmacology, 2026
- Protective effects of empagliflozin on methotrexate induced hepatotoxicity in rats Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024
- SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice The Journal of endocrinology, 2021
- Empagliflozin reduces left ventricular mass increase and improves cardiomyocyte hypertrophy after 5/6 nephrectomy Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025
- Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions Cardiovascular diabetology, 2020
- A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice Biochemical and biophysical research communications, 2022
- Empagliflozin slows down natural kidney senescence via Six1/Wnt4/NF-κB pathway Biogerontology, 2025
- Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia Cells, 2022
- Empagliflozin mitigates methotrexate-induced hepatotoxicity: Targeting ASK-1/JNK/Caspase-3 pathway International immunopharmacology, 2023
- Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice American journal of physiology. Cell physiology, 2024
- Empagliflozin alleviates the development of autoimmune myocarditis via inhibiting NF-κB-dependent cardiomyocyte pyroptosis Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024
- Canagliflozin Inhibits Electrogenic Na+ Transport in Mouse Cortical Collecting Duct Cells Function (Oxford, England), 2025
- Empagliflozin improves cardiac function in rats with chronic heart failure Naunyn-Schmiedeberg's archives of pharmacology, 2024
- Two-hit mouse model of heart failure with preserved ejection fraction combining diet-induced obesity and renin-mediated hypertension Scientific reports, 2025
- Empagliflozin alleviates diabetes-induced cognitive impairments by lowering nicotinamide adenine dinucleotide phosphate oxidase-4 expression and potentiating the antioxidant defense system in brain tissue of diabetic rats Behavioural brain research, 2024
- Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction The journal of physiological sciences : JPS, 2023
- Empagliflozin Attenuates Ferroptosis in Acute Myocardial Infarction via the AMPK/NRF2/SLC7A11 Signaling Pathway International heart journal, 2026
- Metabolomics study reveals the alteration of fatty acid oxidation in the hearts of diabetic mice by empagliflozin Molecular omics, 2022
- Empagliflozin restores cardiac metabolism and suppresses immune activation in acute myocardial infarction Atherosclerosis, 2025
- Empagliflozin decreases ageing-associated arterial stiffening and vascular fibrosis under normoglycemic conditions Vascular pharmacology, 2023
- Empagliflozin as a potential therapy for PCOS: Restoring hormonal balance and ovarian function in a letrozole-induced rat model Tissue & cell, 2026
- Ameliorative Effect of Empagliflozin and Linagliptin on Cisplatin-Induced Nephrotoxicity and Cardiotoxicity by Reducing Oxidative Stress Drug design, development and therapy, 2025
- Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model International journal of molecular sciences, 2022
- Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2/AMPK/Nrf2 Signaling and Targeting Ferroptosis and Autophagy International journal of molecular sciences, 2023
- The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway International immunopharmacology, 2021
- Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis Respiratory physiology & neurobiology, 2020
- Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2025
- Empagliflozin and naringenin mitigate cisplatin-induced testicular injury via modulating NLRP3 inflammasome-mediated pyroptosis: Integrated molecular docking and in vivo evidence Reproductive toxicology (Elmsford, N.Y.), 2026
- Capryol-ethyl oleate self-microemulsifying system for improved intestinal absorption and hypoglycemic activity of empagliflozin Pharmaceutical development and technology, 2026
- Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes Alzheimer's research & therapy, 2020
- Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway Molecular and cellular endocrinology, 2020
- Agomelatine and empagliflozin synergistically protect against diabetic cardiomyopathy via nrf2/HO-1 signaling European journal of pharmacology, 2025
- Biochemical and histopathological evidence for beneficial effects of Empagliflozin pretreatment on acetic acid-induced colitis in rats BMC gastroenterology, 2023
- Cardioprotective effects of short-term empagliflozin treatment in db/db mice Scientific reports, 2020
- Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K+ (KV) Channels International journal of molecular sciences, 2021
- Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress Molecular and cellular endocrinology, 2019
- Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022
- Blockade of cannabinoid CB1 receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy British journal of pharmacology, 2025
- Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical "2-Hit" Model Reveals Autophagy Enhancement Via AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway Journal of the American Heart Association, 2025
- Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure European journal of pharmacology, 2022
- Alterations of myocardial ketone metabolism in heart failure with preserved ejection fraction (HFpEF) ESC heart failure, 2025
- Multiparametric cardiac magnetic resonance identifies macrophage nitric oxide synthase 2-mediated benefits of preventive sodium-glucose cotransporter 2 inhibition in a mouse model of metabolic heart disease Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2025
- Empagliflozin Prevent High-Glucose Stimulation Inducing Apoptosis and Mitochondria Fragmentation in H9C2 Cells through the Calcium-Dependent Activation Extracellular Signal-Regulated Kinase 1/2 Pathway International journal of molecular sciences, 2024
- Characterization of 14-3-3 isoforms expressed in the Echinococcus granulosus pathogenic larval stage Journal of proteome research, 2015
- Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis American journal of physiology. Cell physiology, 2024
- Empagliflozin rescues pro-arrhythmic and Ca2+ homeostatic effects of transverse aortic constriction in intact murine hearts Scientific reports, 2024
- Empagliflozin Alleviates Left Ventricle Hypertrophy in High-Fat-Fed Mice by Modulating Renin Angiotensin Pathway Journal of the renin-angiotensin-aldosterone system : JRAAS, 2022
- Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice Scientific reports, 2019
- Empagliflozin targets Mfn1 and Opa1 to attenuate microglia-mediated neuroinflammation in retinal ischemia and reperfusion injury Journal of neuroinflammation, 2023
- Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022
- Pre-ischaemic empagliflozin treatment attenuates blood-brain barrier disruption via β-catenin mediated protection of cerebral endothelial cells Cardiovascular research, 2025
- Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study Journal of the American Heart Association, 2025
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2015
- A high-sugar diet-induced animal model for insulin resistance, oxidative stress, and diabetic nephropathy: insights into empagliflozin's therapeutic potential International urology and nephrology, 2026
- Unraveling the Potential of Empagliflozin to Counteract 1,2-Dimethylhydrazine-Induced Colorectal Cancer in Rats: Involvement of Redox Imbalance, Inflammatory Cascades, and Unprogrammed Cell Proliferation Journal of biochemical and molecular toxicology, 2026
- SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition Cell metabolism, 2020
- Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model European heart journal, 2025
- Empagliflozin Downregulates AMP-Activated Protein Kinaseα O-GlcNAcylation to Ameliorate Hepatic Steatosis FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025
- Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats Nutrients, 2024
- Using the intravesical delivery route to target the kidney American journal of physiology. Renal physiology, 2026
- Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease International journal of molecular sciences, 2025
- Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling Archives of pharmacal research, 2022
- Mitochondria-Targeted Liposomes Boost Thermogenesis for Adipose Tissue Regulation Advanced healthcare materials, 2026
- Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis Diabetologia, 2023
- Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis Cardiovascular diabetology, 2024
- Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1/AMPK Pathway Cells, 2025
- Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis Cardiovascular diabetology, 2022
- Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic heart failure with preserved ejection fraction model Cardiovascular research, 2025
- A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats Biomedical chromatography : BMC, 2016
- Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule Journal of the American Society of Nephrology : JASN, 2017
- Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis Scientific Reports, 2021
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis Diabetes Research and Clinical Practice, 2021
- SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis EClinicalMedicine, 2021
- Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis Cardiovascular Diabetology, 2022
- The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review International Journal of Molecular Sciences, 2023
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials BMJ, 2021
